We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$216M
AUM Growth
-$2.51M
Cap. Flow
-$7.44M
Cap. Flow %
-3.45%
Top 10 Hldgs %
35.07%
Holding
172
New
38
Increased
33
Reduced
47
Closed
40

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$3.63M
2
CPRI icon
Capri Holdings
CPRI
+$3.52M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$3.22M
4
SPLK
Splunk Inc
SPLK
+$3.13M
5
GPCR icon
Structure Therapeutics
GPCR
+$2.41M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.49M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.86M
3
BKI
Black Knight, Inc. Common Stock
BKI
+$3.59M
4
MMP
Magellan Midstream Partners, L.P.
MMP
+$3.49M
5
AJRD
Aerojet Rocketdyne Holdings
AJRD
+$3.38M

Sector Composition

Rank Sector Weight
1 Healthcare 46.09%
2 Technology 13.85%
3 Consumer Discretionary 6.89%
4 Financials 3.51%
5 Communication Services 3.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
151
DELISTED
KalVista Pharmaceuticals
KALV
– –
-69,567
Closed -$626K
KURA icon
152
Kura Oncology
KURA
$882M
– –
-52,787
Closed -$558K
LBTYK icon
153
Liberty Global Class C
LBTYK
$3.4B
– –
-40,664
Closed -$723K
MSCI icon
154
MSCI
MSCI
$40.8B
– –
-1,448
Closed -$680K
NOV icon
155
NOV
NOV
$7.49B
– –
-42,052
Closed -$675K
NYT icon
156
New York Times
NYT
$10.3B
– –
-16,837
Closed -$663K
OXY icon
157
Occidental Petroleum
OXY
$59B
– –
-12,447
Closed -$732K
PTGX icon
158
Protagonist Therapeutics
PTGX
$9.6B
– –
-29,179
Closed -$806K
RLAY icon
159
Relay Therapeutics
RLAY
$4.38B
– –
-32,197
Closed -$404K
SWTX
160
DELISTED
SpringWorks Therapeutics
SWTX
– –
-11,688
Closed -$306K
TDG icon
161
TransDigm Group
TDG
$68.7B
– –
-759
Closed -$679K
TSM icon
162
TSMC
TSM
$2.19T
– –
-6,675
Closed -$674K
WMG icon
163
Warner Music
WMG
$13.1B
– –
-24,779
Closed -$646K
THRX
164
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-136,719
Closed -$1.28M
MRTX
165
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-15,738
Closed -$569K
MMP
166
DELISTED
Magellan Midstream Partners, L.P.
MMP
– –
-55,927
Closed -$3.49M
WWE
167
DELISTED
World Wrestling Entertainment
WWE
– –
-8,907
Closed -$966K
BKI
168
DELISTED
Black Knight, Inc. Common Stock
BKI
– –
-60,121
Closed -$3.59M
KDNY
169
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-76,021
Closed -$2.92M
DICE
170
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-21,557
Closed -$1M
AJRD
171
DELISTED
Aerojet Rocketdyne Holdings
AJRD
– –
-61,520
Closed -$3.38M
ISEE
172
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-139,552
Closed -$5.49M
3 4 5 6
7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q3 2023 Portfolio in Review

As of Q3 2023, HighVista Strategies held 172 positions worth $216M, down 1.1% from $219M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

HighVista Strategies withdrew a net $7.44M in Q3 2023, closing 40 positions and reducing 47 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $5.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, HighVista Strategies opened a new position in Amedisys worth $3.67M.

  • HighVista Strategies's largest Q3 2023 buy was Amedisys: 39,250 shares worth $3.67M.
  • HighVista Strategies added most to Merus in Q3 2023, an estimated $2.15M increase.
  • HighVista Strategies's biggest Q3 2023 reduction was MoonLake Immunotherapeutics, cutting an estimated $3.86M.
  • HighVista Strategies fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $5.49M.
  • HighVista Strategies's ten largest holdings make up 35% of its $216M portfolio in Q3 2023.
  • HighVista Strategies opened 38 new positions and closed 40 in Q3 2023.
  • HighVista Strategies's portfolio value fell 1.1% quarter-over-quarter to $216M.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.